Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 2/20 | 0.58 |
| ▸ | FAAH | O00519 | 4/20 | 0.53 |
| ▸ | RPA1 | P27694 | 2/20 | 0.52 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | BCL2 | P10415 | 1/20 | 0.51 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.51 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.51 |
| ▸ | MGLL | Q99685 | 1/20 | 0.51 |
| ▸ | APP | P05067 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16876779 | 0.90 | FAAH (0.53) | CA9FAAHCHRNA7MGLLAPP | |
| SCHEMBL1764964 | 0.88 | FAAH (0.53) | CA9FAAHCHRNA7KMT2AMGLL | |
| SCHEMBL2194152 | 0.87 | FAAH (0.54) | CA9FAAHCHRNA7KMT2AMGLL | |
| SCHEMBL2192072 | 0.86 | FAAH (0.57) | CA9FAAHCHRNA7KMT2AMGLL | |
| SCHEMBL9630738 | 0.84 | CA9 (0.77) | CA9FAAHRPA1CHRNA7KMT2A | |
| SCHEMBL2193609 | 0.84 | FAAH (0.60) | CA9FAAHCHRNA7KMT2AMGLL | |
| SCHEMBL1764945 | 0.84 | CHRNA7 (0.62) | CA9FAAHCHRNA7KMT2AMGLL | |
| SCHEMBL1764938 | 0.83 | CHRNA7 (0.61) | CA9FAAHRPA1CHRNA7KMT2A | |
| SCHEMBL2193229 | 0.83 | CA9 (0.65) | CA9FAAHRPA1CHRNA7KMT2A | |
| SCHEMBL6586118 | 0.82 | MAPT (0.57) | KMT2AAPPMAPTADORA1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050272784-A1 | Inhibitors of bacterial Type III protein secretion systems | LI XIAOBING | 2005-12-08 | — | — | US | disclosed |
| WO-2005113522-A1 | AZOLE CARBOXAMIDE INHIBITORS OF BACTERIAL TYPE III PROTEIN SECRETION SYSTEMS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272784-A1 | Inhibitors of bacterial Type III protein secretion systems | GBA3, PSMB3, SEC61B | CA9 3439/4885FAAH 3399/4885RPA1 2985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.